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ABSTRACT  
 
Microcephalic osteodysplastic primordial dwarfism type II (MOPD II, MIM 210720) 
and Seckel syndrome (SCKL, MIM 210600) belong to the primordial dwarfism group 
characterized by intrauterine growth retardation, severe proportionate short stature and 
marked microcephaly. MOPD II is distinct from SCKL by more severe growth retardation, 
radiological abnormalities and absent or mild mental retardation. Seckel syndrome is 
associated with defective ATR-dependent DNA damage signalling. 
In 2008, loss-of-function mutations in the pericentrin gene (PCNT) have been 
identified in 28 patients, including 3 SCKL and 25 MOPDII cases [6, 7]. This gene encodes a 
centrosomal protein which plays a key role in the organization of mitotic spindles.  
The aim of our study was to analyze PCNT in a large series of SCKL-MOPD II cases 
to further define the clinical spectrum associated with PCNT mutations. Among eighteen 
consanguineous families (13 SCKL and 5 MOPDII) and 6 isolated cases (3 SCKL and 3 
MOPD II), we identified  thirteen distinct mutations in 5/16 SCKL and 8/8 MOPDII including  
five stop mutations, five frameshift mutations, two splice site mutations and one apparent 
missense mutation affecting the last base of exon 19. Moreover, we demonstrated that this 
latter mutation leads to an abnormal splicing with a predicted premature termination of 
translation. The clinical analysis of the 5 SCKL cases with PCNT mutations showed that they 
all presented minor skeletal changes and clinical features compatible with MOPDII diagnosis. 
We therefore conclude that, despite variable severity, MOPDII is a genetically homogeneous 
condition due to loss-of function of pericentrin.  
.  
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INTRODUCTION 
 Among the primordial dwarfisms, microcephalic osteodysplastic primordial dwarfism 
type II (MOPD II, MIM 210720) and Seckel syndrome (SCKL, MIM 210600) are both 
characterized by intrauterine growth retardation, severe proportionate short stature and 
microcephaly [1, 2]. MOPDII is distinct from SCKL by the severity of the growth retardation, 
the presence of skeleton abnormalities and the mild/ absent  mental retardation [3]. SCKL is a 
genetically heterogeneous condition associated with defective ATR-dependent DNA damage 
signalling [4]. The only reported genetic defect so far is a hypomorphic mutation in the ATR 
gene (Sckl1, 3q22.1-q24) [5]. In 2008, mutations in the pericentrin gene (PCNT) have been 
identified in 28 patients, including 3 patients with SCKL [6] and 25 with MOPDII [7].This 
gene encodes a centrosomal protein, which acts both at structural and regulatory levels. First, 
pericentrin recruits several structural centrosomal proteins, particularly gamma tubulin ring 
complex which initiates microtubular nucleation and spindle organization [8, 9, 10, 11]. 
Second, it plays a role in cell cycle regulation through its interaction with the ATR pathway 
[6]. All mutations identified so far lead to premature translation termination and are 
responsible for pericentrin loss of function as demonstrated in PCNT-mutated cell lines issued 
from patients with SCKL or MOPDII.  
To further define the clinical spectrum of patients with PCNT mutations, we analyzed 
PCNT in 24 families diagnosed either with SCKL or with MOPD II, including 18 
consanguineous families and 6 cases from unrelated parents. 
 
 PATIENTS AND METHODS 
  
Patients  
Criteria for inclusion in the study were: 
- Intrauterine and postnatal growth retardation with birth weight < -2 SD and postnatal 
height < -4 SD 
- Microcephaly with an occipitofrontal circumference (OFC) < -4 SD 
- Diagnosis of MOPDII or SCKL made by a clinical geneticist. 
Diagnostic assessment was performed for all patients by their clinicians (Table 1). 
Seven of these families were previously clinically reported, by Faivre et al [12] (families 
1,3,7, 8, 11 and 12) and Verloes et al [13] (family 19). Written informed consent was obtained 
from all subjects included in this study.  
 
 4
 Microsatellites marker analysis 
In all consanguineous families, microsatellites analysis of the PCNT locus was first 
performed and PCNT was sequenced only in compatible cases. The PCNT sequence analysis 
was performed in all cases from unrelated parents. Blood samples were obtained with 
informed consent from affected children, parents and unaffected siblings. Genomic DNA was 
extracted using Nucleospin® Blood XL kit (Macherey-Nagel). We established 
lymphoblastoid cell lines by EBV transformation and we performed a primary skin fibroblasts 
culture. Genotyping was performed using 4 flanking (D21S1903, D21S1897, D21SpolyATT, 
D21S1446) and one intragenic-PCNT (PCNT-IG) microsatellite markers in all 
consanguineous families and non-consanguineous families with at least two siblings. 
Mutation analysis 
 PCNT exon and flanking intron sequences were amplified from patient DNA by PCR 
using 49 couples of primers designed with the Primer 3 software (Sequence of primers 
available on request). Sequencing reactions were performed on both strands using the BigDye 
Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems, Foster City, California) 
according to the manufacturer’s instructions. 
 Functional consequences of c.3840G>C( p.Q1280H) mutation 
 RNA was extracted from cultured fibroblasts and cDNA was synthetized using 
primers designed to overlap 2 consecutive exons (Sequence of primers: JUNCTION17/18-5': 
CCTGTCCCACAGCGAAAGAG; JUNCTION18/19-5': ACAGCTCCGGCGCTGGAG; JUNCTION20/21-3': 
GGGTACCCTGAGTCTTGTGCAGC). RT-PCR products were expected to span exons 18 to 20 
and exons 19 to 20. GAPDH expression was used as positive controls.  
 
RESULTS 
 Genotyping analysis showed that 9/18 consanguineous families (4/13 SCKL and 5/5 
MOPDII) were compatible with linkage to the PCNT locus.  
The PCNT sequence analysis performed in these 9 consanguineous families and in 6 
additional cases (from unrelated parents) allowed the identification of 13 distinct mutations in 
13 patients (Table 2). All but one mutation were homozygous and cosegregate with the 
disease. In one patient (case 22), a single heterozygous mutation, inherited from the father, 
was detected. The 13 mutations were located throughout the gene and among them, five were 
nonsense mutations (exons 11, 15, 17, 28 and 34), five were frameshift mutations (exons 14, 
16, 28A, 30), two were splice site mutations (intron 18 and intron 40) and one was an 
apparent missense mutation affecting the last base of exon 19 (c.3840G>C, p.Q1280H). None 
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of the mutations were identified in 400 control chromosomes. The c.3840G>C mutation was 
predicted to alter splicing. This was further confirmed by sequence analysis of RT-PCR 
products which demonstrated exon 19 skipping, predictive of a premature termination of 
translation (p.P1204GfsX11).  
Among the 13 patients, 5 were clinically diagnosed as SCKL (patients12-16) and 8 
were diagnosed as MOPDII (patients 17-24, Table 1). The identification of PCNT mutations 
in 5 SCKL and 8 MOPDII patients prompted us to re-analyze the clinical features of all the 
patients with PCNT mutations and compare them to SCKL patients without mutation. We first 
observed that the five SCKL patients with PCNT mutations (families 12-16) presented a more 
severe growth retardation than the SCKL patients without PCNT mutation (-6 to -8 SD versus 
-4 to -5 SD), but less severe than the MOPDII patients with PCNT mutation (-7 to -13 SD). 
For two of them, the adult height is 120 cm and 140 cm respectively (Figure 1, from Hall JG). 
These patients presented also skeletal anomalies including gracile long bones, metaphyseal 
flaring, carpal condensation, and moderate hip dysplasia (Figures 2, 3, 4). These anomalies 
were not present during the first year of life, became more pronounced with time but were 
often less severe than those classically described in MOPDII patients. Importantly, we did not 
observe similar skeletal anomalies in 6 patients without PCNT mutation and with skeletal 
survey available. Finally, these patients have either normal intelligence or mild mental 
retardation. No difference was observed with respect to age of walking (normal to slightly 
delayed) and developmental course. Early developmental milestones were considered as 
normal with excellent social skills. Learning disability was noted after the age of 5 years. 
None of the 4 adult patients can live independently and they all perform “adapted work”.  
 Other features suggestive of MOPDII diagnosis were present in the clinically 
diagnosed SCKL patients with PCNT mutations including truncal obesity and death at 20 
years of age of rupture of CNS vessels (patient 15), initial feeding difficulties and 
development of typical pigmentation anomalies with time (patients 13 and 14), polycystic 
ovaries (patient  14), subglottic stenosis (patient 13), microdontia (patient 12), high-pitched 
voice, stridor and upper respiratory tract infections (patient 16).  
 Finally, facial features were highly suggestive of MOPD diagnosis for 11 patients with 
PCNT mutations including a broad nose with hypoplastic tip, thin alae nasi, with columella 
lying below the alae nasi, long midface, prominent cheeks, small jaw and large eyes in the 
youngest children. Facial features were also changing with time, variable with the ethnic 
origin (patient 18) and less characteristic in the eldest patient of our series (patient15). By 
contrast facial features of the patients with no PCNT mutation (1-11) were quite variable 
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(Figure S1) mainly dominated by the microcephaly with receiding or short forehead and 
relatively large ears.  
 
DISCUSSION 
 We report here the identification of 13 distinct mutations in 8 MOPDII and 5 SCKL 
patients. As previously reported by Griffith [6] and Rauch [7], mutations are distributed 
throughout the gene. We did not find any recurrent mutations in our series. However, the 
c.3109G>T mutation (exon 15) was previously reported by Rauch et al in a patient also 
originating from Turkey (patient 1). In one patient (patient 22), one mutation only was 
detected by direct sequencing but unfortunately RNA was not available. This might be due to 
the limit of our screening and a partial deletion of PCNT gene cannot be excluded. Our study 
provides also the first example of a “missense” mutation (c.3840G>C) but we demonstrated 
that this mutation impairs exon 19 splicing, leading to premature termination of translation. 
We conclude, as previously suggested, that all identified mutations are loss of function 
mutations.  
We identified PCNT mutations in all MOPDII cases, confirming the genetic 
homogeneity of this disorder. Moreover, the retrospective analysis of the 5 SCKL patients 
with PCNT mutation also suggests that they all belong to the MOPDII spectrum. However, 
they were diagnosed as SCKL, based on the absence of severe skeletal manifestations and on 
their final stature >110 cm, which usually excludes the diagnosis of MOPDII [3]. Our study 
also supports that SCKL spectrum is heterogeneous and suffers from variable definition in the 
literature and from clinicians in practice. Indeed, Seckel syndrome has often been used as a 
generic term used for primordial dwarfism, without more specific diagnosis. Recently, 
D’Angelo and Di Bartolomeo reported two cases of SCKL with intracranial anomalies, 
suggestive of MOPDII diagnosis [16, 17]. Similarly, SCKL patients with bone dysplasia 
suggestive of MOPDII have been reported [18, 19]. From our study, we suggest that MOPDII 
spectrum is wider than previously defined. However, in all patients with PCNT mutations we 
have consistently observed 1) distinct facial features 2) growth retardation <-5SD and 
microcephaly <-4SD, 3) mild to absent mental retardation 4) skeletal manifestations including 
hip dysplasia ranging from short femoral neck to severe coxa vara; carpal condensation, and 
gracile long bones with metaphyseal flaring. Other suggestive features occasionally observed 
included 1) vascular anomalies and cutis marmorata 2) high pitched voice 3) microdontia, 4) 
hyperinsulinism, 5) subglottic stenosis, 6) pigmentation anomalies with areas of hypo- and 
hyperpigmentation. 
 7
 
We also observed in two patients with PCNT mutation a liver involvement varying in 
severity from cytolysis to cirrhosis, with the same histological features than those described in 
the literature for patients with MOPDI diagnosis, consisting in ductular cholestasis, 
inflammatory infiltrate, and giant multinucleate hepatocytes. Although theses findings are not 
specific, they may suggest the existence of biliar epithelium anomalies in MOPDII spectrum 
[20]. 
While this study further demonstrates that MOPDII is caused by PCNT mutations, the 
pathogenic mechanisms underlying the clinical features observed in these patients remain 
unclear [21]. First, microcephaly could be related to structural centrosomal abnormalities 
similar to those observed in primary microcephaly [22]. Second, defect in ATR-dependent 
DNA damage signalling has been demonstrated in other conditions characterized by short 
stature and microcephaly and may thereby also account for short stature observed in MOPDII 
cases [23, 24]. Other specific clinical features like vessels anomalies, generalized bone 
dysplasia and hepatitis remain unexplained so far, since they have not described in patients 
with ATR mutations or other centrosomal genes such as ASPM.  
Finally, O’Driscoll and collaborators suggested that the ATR signalling pathway was 
unusually sensitive to haploinsufficiency and established a correlation between ATR-pathway 
dysfunction and growth retardation [23]. Similarly, Rauch et al reported a significant 
reduction of the mean height of heterozygous MOPDII parents [7]. We did not observe such a 
reduction in the mean of parental heights (ranging from -1 to +2 SD) but ethnical variability 
of growth charts may interfere with parental height analysis.  
In conclusion, we identified 13 PCNT loss of function mutations in 13 patients who all 
presented diagnostic criteria for MOPDII. However, we observed a wider variability in the 
severity of the short stature and skeletal manifestations than previously admitted, modifying 
the MOPDII clinical spectrum. The distinction between SCKL and MOPDII appears to be 
crucial for the appropriate management, keeping in mind the risk of vascular anomalies in 
MOPDII.  
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Legends to figures 
 
 
Figure 1: Comparison of growth curves of patients from our cohort with those of patients 
from MOPD II cohort reported by Hall JG et al (from Hall JG, 2004) 
 
Figure 2: Comparison of Hip X-rays in patients with PCNT mutations. 
Note the hip dislocation and coxa vara more pronounced in MOPD II patients 
 
 Figure 3: Comparison of lower limb X-rays in patients with PCNT mutations. 
Note the gracile long bones in both groups. 
 
Figure 4: Comparison of hand X-rays in patients with PCNT mutations  
Note the carpal fusion, the clinodactyly and the delayed bone age. 
 
Figure S1. Facial features in two sisters with no PCNT mutation (A and B, family 7) and two 
patients with PCNT mutation (C1 and C2, Patient 14; D1 and D2, Patient 17). 
Note in patient with PCNT mutations the characteristic nose with hypoplastic alae nasi, 
prominent cheeks and small jaw while in the two patients with no PCNT mutation the facial 
features are marked by the severe microcephaly with large nose and large ears. 
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Family 
 
 
Ethnic 
origin/ 
Gender 
CS 
/Coefficient 
f 
Birth :  
WOG/ 
Weight(g)/Heigh
t(cm)/HC(cm) 
Postnatal 
growth :  
Weight 
/Height/ 
HC (SDS) 
Mental 
retardati
on 
Other clinical features Radiological features 
1 /SCKL* 
(case 
4[12]) 
Algeria 
F 
Y 
f=1/64 
41/2160/45/32 -4/-4/-4 Mild Café au lait spots. VSD. 
Pyelic bifidity. 
Osteosarcoma 
Mild bowing of the femora 
2/SCKL  NA 
M 
Y NA NA NA  NA 
3/ SCKL* 
(case 
3[12]) 
Mali 
M 
Y 
f=1/8 
FT/2000/40/24 -4/-5 ,5/-10 Severe Hypertonia. Ichtyosis. 
Abnormal gyration pattern  
Slight platyspondyly 
4/SCKL France 
M 
Y 
f=1/16 
NA NA NA NA NA 
5/SCKL Algeria 
 F/F 
Y 
 
NA NA NA NA NA 
6/SCKL Algeria  
M 
Y 
f=1/32 
FT/3300/47/30,5 -4/-4/-6 Mild Hip dislocation.  
Chromosomal breakage 
Normal 
7/SCKL* 
(case 
2[12]) 
Morocco 
F/F 
Y 
f=1/16 
FT/1400/40/28 
FT/NA/40/NA 
 Mild/ 
N 
Delayed puberty. Cataract 
Catarct 
Thoracolumbar scoliosis 
8/SCKL* 
(case 
5[12]) 
Algeria 
M/M/M 
Y 
f=1/16 
FT/2040/43,5/30 
FT/2140//42/NA 
FT/2300/NA/NA 
NA/-5/NA 
NA/-5/NA 
NA/-4/NA 
 Mild Cryptorchidia.Diabetes 
mellitus. Craniosynostosis 
Scoliosis. Thick long bones.  
9/SCKL 
 
Lebanon  
F 
Y 
NA 
NA NA NA NA NA 
10/SCKL France 
F/F 
N FT/2030/41/NA 
NA/NA/NA/NA 
-3.5/-7/-6 
-5/-8/-7.5 
N/ 
Mild 
Pyelic duplicity 
Scoliosis 
NA 
Severe scoliosis 
11/SCKL* 
(case 
6[12]) 
France 
M/F 
 
N NA NA NA NA/-4/-8 
NA/-4/-6 
NA 
12/ 
SCKL* 
(case 
1[12]) 
Morocco 
F/NA 
(TOP) 
Y 
f=1/16 
37/1340/38/28 -8/-8/-8 Mild Microdontia. 
Pyelic ectasia 
Thick diaphyseal cortex. Carpal 
fusion. Gracile long bones. 
Brachymesophalangia 
13/SCKL Morocco 
F 
Y 
f=1/16 
32/950/34/25,5 -5/-8/-6.6 N Café au lait spots, areas of 
depigmention 
 Hepatic cytolysis.  
Subglottic stenosis 
Recurrent upper respiratory 
tract infections 
Coxa vara 
14/SCKL 
 
Pakistan 
F 
Y 
f=1/16 
FT/1650/42/30 -3.5/-7/-5 N Café au lait spots,  
area of depigmentation. 
Polycystic ovaries.  
Chromosomal breakage 
Gracile long bones. Short 
femoral neck.  High vertebral 
bodies. Carpal fusion. 
Overtubulated and thick 
diaphyseal cortex.  
15/SCKL France 
M 
N FT/1720/40/27,3 -2.7/-6/-8 Mild Horseshoe kidney. 
Clinodactyly of fifth finger. 
Rupture of CNS vessels 
leading to death (20 years) 
High vertebral bodies. Thick 
diaphyseal cortex. Short femoral 
neck 
16/SCKL Lebanon 
M 
Y 
F=1/16 
NA/800/30/NA NA/-9/-13 Y Sparse scalp hair. 
Receeding forehead. 
Prominent curved nose, 
Micrognatia. Low set ears.   
Clinodactyly. High-pitched 
voice. Stridor. Upper 
respiratory tract infections 
Brain MRI : minimal bilateral ill-
defined areas of hypersignal 
intensity  in white matter 
(terminal zone of myelination) 
Skeletal X rays: NA 
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Table 1: Clinical and radiological features of the 24 families. 
Patients 1-11: Patients with Seckel diagnosis - PCNT excluded 
Patients 12-16: Patients with Seckel diagnosis - PCNT mutation identified 
Patients 17-24: Patients with MOPDII diagnosis - PCNT mutation identified  
CNS: central nervous system, CS : consanguinity, F: female, FT: full-term pregnancy, HC : head 
circumference, M: male, MOPDII: Patient with microcephalic osteodysplastic primordial dwarfism 
type II syndrome N: no, NA: non available, SCKL: Patient with Seckel syndrome, VSD: ventricular 
septal defect, WOG: week of gestation, Y: presence
17/ 
MOPDII 
Turkey 
M 
Y 
f=1/16 
36/1290/35/27 -6/-9/-7  Mild Poor sucking.Vomiting. 
Hyperlaxity. Horseshoe 
kidney.Hypertonia. 
Subglottic stenosis. 
Recurrent upper respiratory 
tract infections. Micropenis 
High squeaky, nasal voice 
Delayed ossification. Coxa vara 
18/ 
MOPDII 
Sri 
Lanka/ 
M 
Y  
f=1/16 
NA NA/-12/-12 NA Poïkilodermia. Atrial septal 
defect. 
Hypoplastic distal phalanges. 
Carpal fusion. Hip dislocation. 
Overtubulated and thick 
diaphyseal cortex 
19/ 
MOPDII 
* [13] 
Morocco 
F/M 
Y 
f=1/16 
37 /770/30/24 
39/1190/33/27,6 
-7/-11/-12 
-9/-10/-10 
Severe/ 
severe 
Hypertonia. Micropenis. Radial, ulnar, and femoral 
metaphyseal flaring.   
20/ 
MOPDII 
Algeria 
M 
 
Y 
f=1/16 
FT/NA/30/NA -10/-13/-10 Mild Café au lait spots. Moya-
moya disease complicated 
with rupture of CNS vessels.   
Coxa vara. Carpal fusion 
21/ 
MOPDII 
Italy 
M 
 
N 31/585/31/23,5 -8/-12/-12 N Micropenis. Café au lait 
spots . Livedo reticularis. 
Cirrhosis.  High squeaky, 
nasal voice 
Coxa vara 
22/ 
MOPDII  
France 
M 
N 37/1400/40/29,5 -9/-7/-6 N Anemia. Body asymmetry 
Radial head dislocation 
NA 
23/ 
MOPDII  
Morocco 
F 
N  37/870/33,5/24 -6/-7/-9 N High squeaky voice. Café-
au-lait spots 
Coxa vara. Short femoral neck. 
Delayed bone age.  
24/ 
MOPDII 
Morocco 
F 
Y 37/1300/36/26 -5.5/-7/-6.5 N  Cranial multiple osteolysis 
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Table 2: Mutations identified in our series. (#) This mutation was previously identified 
 by Rauch in a MOPDII patient with the same Turkish ethnic background 
 
Family Diagnosis Identified mutation Position  Status Protein 
12 SCKL c.1753C>T Exon 11 homozygous p.Arg585X 
13 SCKL c.3840G>C Exon 19 homozygous p.Gln1280His  
Splicesite : Pro1204Glyfs*11 
14 SCKL c.6176_6189delGTCA
GCTGCCGAAG 
Exon 30 homozygous p.Gln2060Argfs*48 
15 SCKL c.3271_3272delTT Exon 16 homozygous p.Leu1091Valfs*101 
16 SCKL  c.5266dupA Exon 28 homozygous p.Met1756Asnfs*53 
17 MOPDII c.3109G>T Exon 15 homozygous p.Glu1037X (#) 
18 MOPDII c.9099+2T>C Intron 40 homozygous Splicesite 
19 MOPDII c.6316_6325delGTTT
GGAGAGCA 
Exon 30 homozygous p.Leu2106Alafs*18 
20 MOPDII c.2326_2327delGA Exon 14 homozygous p.Glu776Lysfs*3 
21 MOPDII c.3608-2A>G Intron 18 homozygous Splicesite 
22 MOPDII c.5578G>T Exon 28 heterozygous p.Glu1860X 
23 MOPDII c.7338C>A Exon 34 homozygous p.Cys2446X 
24 MOPDII c.3382C>G Exon 17 homozygous p.Gln1128X 
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